Abstract
Squamous cell carcinoma of the head and neck (HNSCC) is a complex disease. Patients with more advanced stages are treated with curative intent by a combination of surgery and radiotherapy, but still about 50% develop a relapse: locally, regionally and at distant sites. This clinical outcome strongly indicates that small histologically undetectable tumor deposits remain at these sites: ‘minimal residual disease’. In this article the different aspects related to minimal residual head and neck cancer will be reviewed shortly. The management of patients with head and neck cancer as well as the clinical problems in diagnosis and treatment will be described. The crucial role of minimal residual disease in head and neck cancer will be defined and diagnostic approaches to address the problem will be reviewed. We argue that the infiltration and dissemination of HNSCC takes place beyond the level of histopathological detection, and further that molecular staging will at least in part fill in the gap between anatomical TNM staging and the clinical outcome. However, it is not only the presence of infiltrated or disseminated tumor cells that will determine the prognosis. Also the biological characteristics of the tumor cells at the various sites are important for the clinical follow-up. Promising therapeutic approaches to deal with minimal residual disease will be discussed shortly. Finally the issues ‘field cancerization’ and second primary tumors in head and neck cancer are addressed as these are closely linked to local recurrence and distant metastases. Moreover, second primary tumors will gain more importance when the primary disease and the frequency of relapses are better controlled.
Similar content being viewed by others
References
Boring CC, Squires TS, Tong T: Cancer statistics, 1992. CA Cancer J Clin. 42: 19–38, 1992
Howaldt HP, Kainz M: Projektbericht des Zentralregisters der Deutsch-Österreichisch-Schweizerischen Arbeiteitskreises für Tumoren im Kiefer-und Gesichtsbereich November 1997
Franceschi D, Gupta R, Spiro RH, Shah JP: Improved survival in the treatment of squamous carcinoma of the oral tongue. Am J Surg 166: 360–365, 1993
Zarbo RJ, Crissman JD: The surgical pathology of head and neck cancer. Semin Oncol 15: 10–19, 1988
Alvi A, Johnson JT: Development of distant metastasis after treatment of advanced-stage head and neck cancer. Head and Neck 19: 500–505, 1997
Vikram B: Changing patterns of failure in advanced head and neck cancer. Arch-Otolaryngol 110: 564–565, 1984
Hannahs KJ, Hooper JA, Sigler A: Nursing care of the head and neck cancer patient. In: Suen JY, Myers EN (eds) Cancer of the Head and Neck. Churchill Livingstone, New York, 1981 pp 839
Callery CD, Spiro RH, Strong EW: Changing trends in the management of squamous carcinoma of the tongue. Am J Surg 148: 449–454, 1984
Crile G: Excision of cancer of the head and neck — with special reference to the plan of dissection based on one hundred and thirty-two operations. J Am Med Assoc 47: 1780–1787, 1906
Brizel DM, Albers ME, Fisher SR, Scher RL, Richtsmeier WJ, Hars V, George SL, Huang AT, Prosnitz LR: Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck. N Engl J Med 338: 1798–1804, 1998
Goepfert H: Are we making any progress? Arch Otolaryngol 110: 562–563, 1984; McGuirt WF, Johnson JT, Myers EN, Rothfield R, Wagner R: Floor of mouth carcinoma. The management of the clinically negative neck: Arch Otolaryngol Head Neck Surg 121: 278–282, 1995
Petruzzelli GJ, Benefield J, Yong S: Mechanism of lymph node metastases: current concepts. Otolaryngol Clin North Am 31: 585–599, 1998
Tupchong L, Scott CB, Blitzer PH, Marcial VA, Lowry LD, Jacobs JR, Stetz J, Davis LW, Snow JB, Chandler Rl: Randomized study of preoperative versus postoperative radiation therapy in advanced head and neck carcinoma: long-term follow-up of RTOG study 73–03. Int J Rad Oncol 20: 21–28, 1991
Vokes EE, Weichselbaum RR, Lippman SM, Hong KW: Medical progress; head and neck cancer; N Eng J Med 328: 184–194, 1993
Zelefsky MJ, Raben A, Strong EW, et al.: Long term results of postoperative radiotherapy for squamous cell cancers of the head and neck (abstract 289). Proceedings of the fourth International Conference on head and neck cancer, July 1996, Toronto
Fisher B, Fisher ER: Barrier function of lymph node to tumor cells and erythrocytes; I Normal nodes; II Effect of X-Ray/inflammation/sensitization and tumor growth. Cancer 20: 1907–1919, 1967
Jones AS, Roland NJ, Field JK, Phillips DE: The level of cervical lymph node metastases: their prognostic relevance and relationship with head and neck squamous carcinoma primary sites. Clin Otolaryngol 19: 63–69, 1994
Snow GB, Annyas AA, van Slooten EA, Bartelink H, Hart AAM: Prognostic factors of neck node metastasis. Clin Otolaryngol 7: 185–192, 1982
Leemans CR, Tiwari R, Nauta JJ, Van der Waal I, Snow GB: Regional lymph node involvement and its significance in the development of distant metastases in head and neck carcinoma. Cancer 71: 452–456, 1993
Violaris NS, O'Neil D, Helliwell TR, Caslin AW, Roland NJ, Jones AS: Soft tissue cervical metastases of squamous carcinoma of the head and neck. Clin Otolaryngol 19: 394–399, 1993
Mendelson BC, Woods JE, Beahrs OH: Neck dissection in the treatment of carcinoma of the anterior two-thirds of the tongue. Surg Gynal Obstet 143: 75–80, 1976
Krause CJ, Lee JG, McCabe BF: Carcinoma of the oral cavity. Arch Otolaryngol 97: 354–358, 1973
Lindberg R: Distribution of cervical lymph node metastases from squamous cell carcinoma of the upper respiratory and digestive tracts. Cancer 29: 1446–1449, 1972
Shah JP, Candela FC, Poddar AK: The patterns of cervical lymph node metastases from squamous carcinoma of the oral cavity. Cancer 66: 109–113, 1990
Shah JP: Patterns of cervical lymph node metastasis from squamous carcinomas of the upper aerodigestive tract. Am J Surg 160: 405–409, 1990
Candela FC, Kothari K, Shah JP: Patterns of cervical node metastases from squamous carcinoma of the oropharynx and hypopharynx. Head & Neck 12: 197–203, 1990
Candela FC, Shah J, Jaques DP, Shah JP: Patterns of cervical node metastases from squamous carcinoma of the larynx. Arch Otolaryngol Head Neck Surg 4: 432–435, 1990
Bataini JP, Bernier J, Brugere J, Jaulerry Ch, Picco Ch, Brunin F: Natural history of neck disease in patients with squamous cell carcinoma of oropharynx and pharyngolarynx. Radiother Oncol 3: 245–255, 1985
Lindberg RD: Distribution of cervical lymph node metastases from squamous cell carcinoma of the upper respiratory and digestive tracts. Cancer 29: 1446–1449, 1972
Kinsey DL, James AG, Bonta JA: A study of metastatic carcinoma of the neck. Ann Surg 147: 366–374, 1958
Byers RM, Wolf PF, Ballantyne AJ: Rationale for elective modified neck dissection. Head Neck Surg 3: 160–167, 1988
Byers RM, Weber RS, Andrews T, McGill D, Kare R, Wolf P: Frequency and therapeutic implications of ‘skip metastases’ in the neck from squamous carcinoma of the oral tongue. Head & Neck 19: 14–19, 1997
Dennington ML, Carter DR, Meijers AD: Distant metastases in head and neck carcinoma. Laryngoscope 90: 196–201, 1980
Nishijima W, Takooda S, Tokita N, Takayama S, Sakura M: Analyses of distant metastases in squamous cell carcinoma of the head and neck and lesions above the clavicle at autopsy. Arch Otolaryngol Head Neck Surg 119: 65–68, 1993
Zbären P, Lehmann W: Frequency and sites of distant metastases in head and neck squamous cell carcinoma. An analysis of 101 cases at autopsy. Arch Otolaryngol Head Neck Surg 113: 762–764, 1987
Spiro RH: The management of neck nodes in head and neck cancer: a surgeon's view. Bull NY Acad Med 61: 629–637, 1985
Vernham GA, Crowther JA: Head and neck carcinoma — stage at presentation. Clin Otolaryngol 19: 120–124, 1994
McGuirt WF, Johnson JT, Myers EN, Rothfield R, Wagner R: Floor of mouth carcinoma. The management of the clinically negative neck. Arch Otolaryngol Head Neck Surg 121: 278–282, 1995
Yuen AP, Wie WI, Wong YM, Tang KC: Elective neck dissection versus observation in the treatment of early oral tongue carcinoma. Head Neck 19: 583–588, 1997
Van den Brekel MWM, Castelijns JA, Snow GB: Detection of lymph node metastases in the neck: radiologic criteria. Radiology 192: 617–618, 1994
Som PM: Detection of metastasis in cervical lymph nodes: CT and MRD criteria and differential diagnosis. Am J Rad 158: 961–969, 1992
Don DM, Anzai Y, Lufkin RB, Fu Y, Calcaterra TC: Evaluation of cervical lymph node metastases in squamous cell carcinoma of the head and neck. Laryngoscope 105: 669–674, 1995
Van den Brekel MWM, Castelijns JA, Snow GB: The size of lymph nodes in the neck on sonograms as a radiologic criterion for metastasis: How reliable is it. Am J Neuroradiol 19: 2191–2197, 1998
Bier J: Radical neck dissection versus conservative neck dissection for squamous cell carcinoma of the oral cavity. Rec Res Cancer Res 134: 57–62, 1994
Van den Brekel MWM, Castelijns JA, Stel HV, Luth WJ, Valk J, van der Waal I, Snow GB: Occult metastatic neck disease: detection with US and US-guided fine-needle aspiration cytology. Radiology 180: 457–461, 1991
McIvor NP, Freeman JL, Salem S, Elden L, Noyek AM, Bedard YC: Ultrasonography and ultrasound-guided fine-needle aspiration biopsy of head and neck lesions: a surgical perspective. Laryngoscope 104: 669–674, 1994
Van den Brekel MWM, Castelijns JA, Stel HV, Golding RP, Meyer CJ, Snow GB: Modern imaging techniques and ultrasound-guided aspiration cytology for the assessment of neck node metastases: a prospective comparative study. Eur Arch Otorhinolaryngol 250: 11–17, 1993
Strong EW: How does the site and the stage of the primary and ist therapy influence the treatment of the patient with the N0 neck? Proceedings of the Fourth International Conference on Head and Neck Cancer Vol IV: 548–556, 1996
Loree TR, Strong EW: Significance of positive margins in oral cavity squamous carcinoma. Am J Surg 160: 410–414, 1990
Brennan JA, Mao L, Hruban RH, Boyle JO, Eby YJ, Koch WM, Goodman SN, Sidransky D: Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. N Engl J Med 332: 429–435, 1995
Davidson TM, Nahum AM, Astarita RW: Microscopic controlled excisions for epidermoid carcinoma of the head and neck. Otolaryngol, Head Neck Surg 89: 244–251, 1981
Davidson TM, Haghighi P, Baird S, Astarita RW, Seagren S: MOHS for head and neck mucosal cancer: report on 111 patients. Laryngoscope 98: 1078–1083, 1988
Davidson TM, Nahum AM, Haghighi P, Astarita RW, Saltzstein SL, Seagren S: The biology of head and neck cancer: detection and control by parallel histologic sections. Arch Otolaryngol 110: 193–196, 84
Rouviere H: Anantomy of the Human Lymphatic System. Ann Arbor: Edwards Brothers, 1938
Fisch UP, Sigel ME: Cervical lymphatic system as visualized by lymphography. Ann Otol 73: 869–883, 1964
Huang XZ, Wu JF, Spong S, Sheppard D: The integrin alpha-v-beta-6 is critical for keratinocyte migration on both its known ligand, fibronectin, and on vitronectin. J Cell Sci 111: 2189–2195, 1998
Pilcher BK, Dumin JA, Sudbeck BD. Krane SM, Welgus HG, Parks WC: The activity of collagenase-1 is required for keratinocyte migration on a type I collagen matrix. J Cell Biol 137: 1445–1457, 1997
van den Brekel MWM, Stel HV, Valk P, van der Waal I, Meyer CJLM, Snow GB: Micrometastases from squamous cell carcinoma in neck dissection specimens. Eur Arch Otorhinolaryngol 249: 349–353, 1992
Voit C, Schoengen A, Peter RU: Increased sensitivity in early detection of submicroscopic lymph node metastases in melanoma patients. Brit J Cancer 77Suppl 1: 29, 1998
Pantel K: Detection of minimal disease in patients with solid tumors. J Hematother 5: 359–367, 1996
Pantel K, Braun S, Passlick B, Schlimok G: minimal residual epithelial cancer: diagnostic approaches and prognostic relevance. Progr. Histochem. Cytochem 30: 1–61, 1996
Schlimok G, Funke I, Holzmann B, Gottlinger G, Schmidt G, Hauser H, Swierkot S, Warnecke HH, Schneider B, Koprowski H, Riethmüller G: Micrometastatic cancer cells in bone marrow: in vitro detection with anti-cytokeratin and in vivo labeling with anti–17–1A monoclonal antibodies. Proc Natl Acad Sci 84: 8672–8676, 1987
Pantel K, Izbicki J, Passlick B, Angstwurm M, Häussinger K, Thetter O, Riethmüller G: Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small-cell lung cancer without overt metastases. Lancet 347: 649–653, 1996
Lindemann F, Schlimok G, Dirschedl P, Witte J, Riethmüller, G: Prognostic significance of micrometastatic tumor cells in bone marrow of colorectal cancer. Lancet 340: 685–689, 1992
Gath HJ, Heissler E, Hell B, Bier J, Riethmuller G, Pantel K: Immunocytologic detection of isolated tumor cells in bone marrow of patients with squamous cell carcinomas of the head and neck region. Int J Oral Maxillofac Surg 24: 351–355, 1995
Wollenberg B, Ollesch A, Maag K, Funke I, Wilmes E: Mikromettasen im knockenmark von patienten mit karzinomen des kopf-hals-bereiches. Laryngo Rhino Otol 73: 88–93, 1994
Zippelius A, Kufer P, Honold G, Kollermann MW, Oberneder R, Schlimok G, Riethmuller G, Pantel K: Limitations of reverse-transcriptase polymerase chain reaction analyses for detection of micrometastatic epithelial cancer cells in bone marrow. J Clin Oncol 15: 2701–2708, 1997
Dingemans A-MC, Brakenhoff RH, Postmus PE, Giaccone G. Detection of cytokeratin 19 transcripts by reverse transcriptase polymerase chain reaction in lung cancer cell lines and blood of lung cancer patients. Lab Invest 77: 213–220, 1997
Califano J, van der Riet P, Westra W, Nawroz H, Clayman G, Piantadosi S, Corio R, Lee D, Greenberg B, Koch W, Sidransky D: Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 56: 2488–2492, 1996
Sidransky D, Von Eschenbach A, Tsai YC, Jones P, Summerhayes I, Marschall F, Paul M, Green P, Hamilton SR, Frost P, Vogelstein B: Identification of p53 gene mutations in bladder cancers and urine samples. Science 252: 706–709, 1991
Mao L, Lee DJ, Tockman MS, Erozan YS, Askin F, Sidransky D: Microsatellite alterations as clonal markers for the detection of human cancer. Proc Natl Acad Sci USA 91: 9871–9875, 1994
Sidransky D: Nucleic acid-based methods for the detection of cancer. Science 278: 1054–1059, 1997
Steiner G, Schoenberg MP, Linn JF, Mao L, Sidransky D: Detection of bladder cancer recurrence by microsatellite analysis of urine. Nature Med 3: 621–624, 1997
Traweek ST, Liu J, Battifora H: Keratin gene expression in non-epithelial tissues: detection with polymerase chain reaction. Am J Pathol 142: 1111–1118, 1993
Izbicki JR, Hosch SB, Pichlmeier U, Rehders A, Busch C, Niendorf A, Passlick B, Broelsch CE, Pantel K: Prognostic value of immunohistochemically identifiable tumor cells in lymph nodes of patients with completely resected esophageal cancer. N Eng J Med 337: 1188–1194, 1997
Liefers GJ, Cleton-Jansen AM, van de Velde CJ, Hermans J, van Krieken JH, Cornelisse CJ, Tollenaar RA: Micrometastases and survival in stage II colorectal cancer. N Eng J Med 339: 223–228, 1998
Hynes RO: Integrins: versality, modulation, and signalling in cell adhesion. Cell 69: 11–25, 1992
Jones PH, Harper S, Watt FM: Stem cell patterning and fate in human epidermis. Cell 80: 83–93, 1995
Watt FM, Jones PH: Expression and function of the keratinocyte integrins. Development Suppl: 185–192, 1993
Jones PH, Watt FM: Separation of human epidermal stem cells from transit amplifying cells on the basis of differences in integrin function and expression. Cell 73: 713–724, 1993
Wolf GT, Carey TE, Schmaltz SP, McClatchey KD, Poore J, Glaser L, Hayashida DJ, Hsu S: Altered antigen expression predicts outcome in squamous cell carcinoma of the head and neck. J Nat Cancer Inst 82: 1566–1572, 1990
Jones J, Watt FM, Speight PM: Changes in the expression of alpha v integrins in oral squamous cell carcinomas. J Oral Pathol Med 26: 63–68, 1997
Thomas GJ, Jones J, Speight PM: Integrins and oral cancer. Oral Oncol 33: 381–388, 1997
Zhang K, Kim, JP, Woodley DT, Waleh NS, Chen YQ, Kramer RH: Restricted expression and function of laminin 1-binding integrins in normal and malignant oral mucosal keratinocytes. Cell-Adhes-Commun 4: 159–174, 1996
Cortesina G, Bussi M, Carlevato MT, Ferro S, Panizzut B, Cavalot AL, Gervasio CF, Marchisio PC: Significance of adhesion molecules as biological prognostic factor in locally advanced laryngeal squamous cell carcinomas. Acta Otolaryngol Stockh 116: 350–352, 1996
Vassalli JD, Saurat JH: Cuts and scrapes? Plasmin heals. Nature Med 2: 284–285, 1996
Reinartz J, Schaefer B, Bechtel MJ, Kramer MD: Plasminogen activator inhibitor type-2 (PAI-2) in human keratinocytes regulates pericellular urokinase-type plasminogen activator. Exp Cell Res 223: 91–101, 1996
Kramer MD, Schaefer B, Reinartz J: Plasminogen activation by human keratinocytes: molecular pathways and cell-biological consequences. Biol Chem Hoppe-Seyler 376: 131–141, 1995
Boyd D: Invasion and metastasis, Cancer Metas Rev 15: 77–89, 1996
Schmitt M, Janicke F, Graeff H: Tumor-associated proteases. Fibrinolysis 4 Suppl: 3–26, 1992
Parolini S, Flagiello D, Cinquetti A, Gozzi R, Cristini S, Cappiello J, Nicolai P, Rusnati M, Presta M, Tosatti MM: Up-regulation of urokinase-type plasminogen activator in squamous cell carcinoma of human larynx. Br J Cancer 74: 1168–1174, 1996
Kook YH, Adamski J, Zelent A, Ossowski L: The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy. EMBO J 13: 3983–3991, 1994
Young MR, Wright MA, Lozano Y, Matthews JP, Benefield J, Prechel MM, Mechanisms of immune suppression in patients with head and neck cancer: influence on the immune infiltrate of the cancer. Int J Cancer 67: 333–338, 1996
Uhr JW, Scheuermann RH, Street NE, Vitetta ES: Cancer dormancy: opportunities for new therapeutic approaches. Nature Med 3: 505–509, 1997
Jacobs C, Makuch R: Efficacy of adjuvant chemotherapy for patients with resectable head and neck cancer: A subset analysis of the Head and Neck Contracts Program. J Clin Oncol 8: 838–847, 1990
Schuller DE, Metch B, Mattox D, McCracken JD: Prospective chemotherapy in advanced head and neck cancer: Final report of the Southwest Oncology Group. Laryngoscope 98: 1205–1211, 1988
Laramore GE, Scott CB, al-Sarraf M, Haselow RE, Ervin TJ, Wheeler R, Jacobs JR, Schuller DE, Gahbauer RA, Schwade JG: Adjuvant chemotherapy for resectable squamous cell carcinomas of the head and neck: report on Intergroup Study 0034. Int J Radiat Oncol 23: 705–713, 1992
Sanchiz F, Milla A, Torner J, Bonet F, Artola N, Carreno L, Moya LM, Riera D, Ripol S, Cirera L: Single fraction per day versus two fractions per day versus radiochemotherapy in the treatment of head and neck cancer. Int J Radiat Oncol 19: 1347–1350, 1990
Browman GP, Cripps C, Hodson DI, Eapen L, Sathya J, Levine MN: Placebo-controlled randomized trial of infusional fluorouracil during standard radiotherapy in locally advanced head and neck cancer. J Clin Oncol 12: 2648–2653, 1994
Merlano M, Corvo R, Margarino M, Benasso M, Rosso R, Sertoli MR, Cavallari M, Scala M, Guenzi M, Siragusa A: Combined chemotherapy and radiation therapy in advanced inoperable squamous cell carcinoma of the head and neck. The final report of a randomized trial. Cancer 67: 915–921, 1991
Stupp R, Vokes E: Chemotherapy of head and neck tumors. In: Thawley SE, Panje WR, Batsakis JG, Lindberg RD (eds) Comprehensive Management of Head and Neck Tumors. W.B. Saunders Company, Philadelphia. 1999. Vol 1, pp 141–156
Rentschler RE, Wilbur DW, Petti GH, Chonkich GD, Hilliard DA, Camacho ES, Thorpe RB: Adjuvant methotrexate escalated to toxicity for resectable stage III and IV squamous head and neck carcinomas — a prospective, randomized study. J Clin Oncol 5: 278–285, 1987
Johnson JT, Myers EN, Schramm VL, Mayernik DG, Nolan TA, Sigler BA, Wagner RL: Adjuvant chemotherapy for high-risk squamous-cell carcinoma of the head and neck. J Clin Oncol 5: 456–458, 1987
Whiteside TL, Rabinowich H: The role of Fas/FasL in immunosuppression induced by human tumors. Cancer Immunol Immunother 46: 175–184, 1998
Reichert TE, Rabinowich H, Johnson JT, Whiteside TL: Mechanisms responsible for signaling and functional defects. J Immunother 21: 295–306, 1998
De Bree R, Roos JC, Quak JJ, Den Hollander W, Snow GB, Van Dongen GAMS: Clinical screening of monoclonal antibodies 323/A3, cSF-25, and K928 for suitability of targeting tumors in the upper-aerodigestive and respiratory tract. Nucl Med Commun 15: 613–627, 1994
De Bree R, Roos JC, Quak JJ, Den Hollander W, Van den Brekel MWM, Van De Wal JE, Snow GB, Van Dongen GAMS: Clinical imaging of head and neck cancer with 99mTc-labeled monoclonal antibody E48 IgG or F(ab′)2. J Nucl Med 35: 775–783, 1994
De Bree R, Roos JC, Quak JJ, Den Hollander W, Snow GB, Van Dongen GAMS: Radioimmunoscintigraphy with 99m-Tc-labeled monoclonal antibody U36 and its biodistribution in patients with head and neck cancer. Clin Cancer Res 1, 591–598, 1995
De Bree R, Roos JC, Quak JJ, Den Hollander W, Wilhelm AJ, Van Lingen A, Snow GB, Van Dongen GAMS: Biodistribution and pharmacokinetics of radiolabeled monoclonal antibodies E48 IgG and F(ab′)2 in patients with head and neck cancer. Clin Cancer Res 1: 277–286, 1995
Van Gog FB, Visser GW, Stroomer JW, Roos JC, Snow GB, van Dongen GA: High dose rhenium-186-labeling of monoclonal antibodies for clinical application: pitfalls and solutions. Cancer 80 Suppl: 2360–2370, 1997
Van Dongen GAMS, Brakenhoff RH, De Bree R, Gerretsen M, Quak JJ, Snow GB: Progress in radioimmunotherapy of head and neck cancer. Oncology Rep 1: 259–264, 1994
Gerretsen M, Visser GWM, Brakenhoff RH, Van Walsum M, Snow GB, Van Dongen GAMS: Complete ablation of small head and neck cancer xeno-grafts with 186Re-labeled MAb E48 IgG. Cell Bioph 24: 135–142, 1994
Gerretsen M, Visser GWM, van Walsum M, Meijer CJLM, Snow GB, Van Dongen GAMS: 186Re-labeled monoclonal antibody E48 IgG mediated therapy of human head and neck squamous cell carcinoma xenografts. Cancer Res 53: 3524–3229, 1995
Van Gog FB, Brakenhoff RH, Stigter-van Walsum M, Snow GB, van Dongen GA: Perspectives of combined radioimmunotherapy and anti-EGFR antibody therapy for the treatment of residual head and neck cancer. Int J Cancer 77: 13–18, 1998
Clayman GL, el-Naggar AK, Roth JA, Zhang WW, Goepfert H, Taylor DL, Liu TJ: In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. Cancer Res 55: 1–6, 1995
Clayman GL, el-Naggar AK, Lippman SM, Henderson YC, Frederick M, Merritt JA, Zumstein LA, Timmons TM, Liu TJ, Ginsberg L, Roth JA, Hong WK, Bruso P, Goepfert H: Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol 16: 2221–2232, 1998
Breau RL, Clayman GL: Gene therapy for head and neck cancer. Curr Opin Oncol 8: 227–231, 1996
Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A, McCormick F: An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274: 373–376, 1996
Heise C, Sampson-Johannes A, Williams A, McCormick F, Vonhoff DD, Kirn DH: Onyx-015, an E1b gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nature Med 3: 639–645, 1997
Hall AR, Dix BR, O'Carroll SJ, Braithwaite AW: p53-dependent cell death/apoptosis is required for a productive adenovirus infection. Nature Med 4: 1068–1072, 1998
Rothmann T, Hengstermann A, Whitaker NJ, Scheffner M, Zurhausen H: Replication of onyx-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J Virol 72: 9470–9478, 1998
Rocco JW, Li D, Liggett WH Jr, Duan L, Saunders JK Jr, Sidransky D, O'Malley BW Jr: p16INK4A adenovirus-mediated gene therapy for human head and neck squamous cell cancer. Clin Cancer Res 4: 1697–1704, 1998
Douglas JT, Rogers BE, Rosenfeld ME, Michael SI, Feng M, Curiel DT. Targeted gene delivery by tropism-modified adenoviral vectors. Nature Biotech 14: 1574–1578, 1996
Dmitriev I, Krasnykh V, Miller CR, Wang MH, Kashentseva E, Mikheeva G, Belousova N, Curiel DT: An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 72: 9706–9713, 1998
Cooper JS, Pajak TF, Rubin P, Tupchong L, Brady LW, Leibel SA, Laramore GE, Marcial VA, Davis LW, Cox JD: Second malignancies in patients who have head and neck cancer: incidence, effect on survival and implications based on the RTOG experience. Int J Radiat Oncol 17: 449–456, 1989
Licciardello JT, Spitz MR, Hong WK: Multiple primary cancer in patients with cancer of the head and neck: second cancer of the head and neck, esophagus, and lung. Int J Radiat Oncol 17: 467–476, 1989
Schaart LH, Ozsahin M, Zhang GN, Touboul E, De-Vataire F, Andolenko P, Lacau-Saint-Guily J, Laugier A, Schlienger M: Synchronous and metachronous head and neck carcinomas. Cancer 74: 33–38, 1994
Slaughter DP, Southwick HW, Smejkal W: ‘Field cancerisation’ in oral stratified squamous epithelium: Clinical implication of multicentric orgin. Cancer 6: 963–968, 1953
Warren S, Gates O: Multiple primary malignant tumors: a survey of the literature and a statistical study. Am J Cancer 16: 1358–1414, 1932
Hong WK, Lippman SM, Itri LM, Karp DD, Lee JS, Byers RM, Schantz SP, Kramer AM, Lotan R, Peters LJ: Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 323: 795–801, 1990
Bedi GC, Westra WH, Gabrielson E, Koch W, Sidransky D: Multiple head and neck tumors: evidence for a common clonal origin. Cancer Res 56: 2484–2487, 1996
Leong PP, Rezai B, Koch WM, Reed A, Eisele D, Lee DJ, Sidransky D, Jen J, Westra WH: Distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma. J Nat Cancer Inst 90: 972–977, 1998
Cloos J, Braakhuis BJM, Steen I, Copper MP, de Vries N, Nauta JJP, Snow GB: Increased mutagen sensitivity in head-and-neck squamous-cell carcinoma patients, particularly those with multiple primary tumors. Int J Cancer 56: 816–819, 1994
Cloos J, Spitz MR, Schantz SP, Hsu TC, Zhang Z, Tobi H, Braakhuis BJM, Snow GB: Genetic susceptibility to head and neck squamous cell carcinoma. J Natl Cancer Inst 88: 530–535, 1996.
De Vries N, Van Zandwijk N, Pastorino U: Chemoprevention of second primary tumours in head and neck cancer in Europe: Euroscan. Eur J Cancer 30B: 367–368, 1994
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gath, H.J., Brakenhoff, R.H. Minimal Residual Disease in Head and Neck Cancer. Cancer Metastasis Rev 18, 109–126 (1999). https://doi.org/10.1023/A:1006268621730
Issue Date:
DOI: https://doi.org/10.1023/A:1006268621730